LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

3.39 -0.59

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.35

Max

3.39

Galvenie mērījumi
By Trading Economics
Ienākumi	5.5M -28M
Pārdošana	8.2M 13M
Peļņas marža	-208.694
Darbinieki	172
EBITDA	8.7M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+352.21% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-48M 206M
Iepriekšējā atvēršanas cena	3.98
Iepriekšējā slēgšanas cena	3.39

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. febr. 16:32 UTC

Peļņas

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026. g. 14. febr. 22:02 UTC

Peļņas

Looking for Dividends? Consider Europe. -- Barrons.com

2026. g. 14. febr. 09:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 13. febr. 21:57 UTC

Peļņas

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026. g. 13. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 13. febr. 21:20 UTC

Peļņas

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026. g. 13. febr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Dollar Pares Down Early Losses -- Market Talk

2026. g. 13. febr. 20:39 UTC

Tirgus saruna

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026. g. 13. febr. 20:28 UTC

Tirgus saruna

Oil Settles Week Lower -- Market Talk

2026. g. 13. febr. 19:51 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:29 UTC

Peļņas

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026. g. 13. febr. 18:18 UTC

Iegādes, apvienošanās, pārņemšana

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026. g. 13. febr. 17:52 UTC

Peļņas

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026. g. 13. febr. 17:16 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 17:10 UTC

Iegādes, apvienošanās, pārņemšana

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026. g. 13. febr. 16:59 UTC

Peļņas

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026. g. 13. febr. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026. g. 13. febr. 16:11 UTC

Peļņas

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026. g. 13. febr. 16:07 UTC

Tirgus saruna

Hungarian Forint Could Rise Further -- Market Talk

2026. g. 13. febr. 15:54 UTC

Peļņas

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026. g. 13. febr. 15:26 UTC

Tirgus saruna

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026. g. 13. febr. 15:01 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026. g. 13. febr. 15:00 UTC

Peļņas

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026. g. 13. febr. 14:50 UTC

Tirgus saruna

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026. g. 13. febr. 14:44 UTC

Peļņas

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026. g. 13. febr. 14:22 UTC

Tirgus saruna

Peļņas

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

352.21% augšup

Prognoze 12 mēnešiem

Vidējais 15.33 USD 352.21%

Augstākais 25 USD

Zemākais 10 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.